Search

everythinglearnresearchcommunity

for

Search:↓

Mice genetically modified to produce more CD109 in their skin had less inflammation and better healing with less scarring.

Activin increases skin tumor formation, skin Tregs help hair growth, lymph-node removal doesn't improve melanoma survival, cells can revert to stem cells in wound healing, and skin bacteria produce peptides that may treat infections.

Interleukin 6 may help protect skin without causing inflammation.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Hsa-miR-193a-5p is important in alopecia areata by promoting inflammation and involving specific genes in hair and immune function.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

New treatments for alopecia areata show promise in improving hair loss outcomes.

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

The mTOR signaling pathway might play a role in radiation dermatitis, but more research is needed.

Blocking IL-17 can reduce joint inflammation in Ross River Virus infections.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

The calcineurin/NFAT pathway plays a significant role in the development and growth of a type of skin cancer called cutaneous squamous cell carcinoma.

Injecting certain cells into mice caused hair loss, which was preventable with a specific inhibitor.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

The document concludes that DNA methylation and the mTOR pathway are important for stem cell function and could impact disease treatment.

IL-1β inhibits human hair follicle growth.

Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.

ceRNA networks offer potential treatments for skin aging and wound healing.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

Alarmin cytokines are key in controlling skin immunity and inflammation.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.